These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 2893407)

  • 1. Neuroleptic effects on platelet aggregation: a study in normal volunteers and schizophrenics.
    Dinan TG
    Psychol Med; 1987 Nov; 17(4):875-81. PubMed ID: 2893407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of neuroleptic drugs on 5-hydroxytryptamine induced platelet aggregation in schizophrenic patients.
    Orr MW; Knox JM; Allen R; Gelder MG; Grahame-Smith DG
    Br J Clin Pharmacol; 1981 Mar; 11(3):255-9. PubMed ID: 6111333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationalizing neuroleptic polypharmacy in chronic schizophrenics: effects of changing to a single depot preparation.
    Soni SD; Sampath G; Shah A; Krska J
    Acta Psychiatr Scand; 1992 May; 85(5):354-9. PubMed ID: 1351333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Tardive dyskinesia induced by classical antipsychotic drugs: a Tunisian sample of schizophrenics].
    Sejil I; Oumaya A; Bouguerra C; Mehdi F; Bellaaj R; Gallali S
    Encephale; 2013 May; 39 Suppl 1():S36-41. PubMed ID: 23219594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two cases of agranulocytosis on addition of a butyrophenone to a long-standing course of phenothiazine treatment.
    Young A; Kehoe R
    Br J Psychiatry; 1989 May; 154():710-2. PubMed ID: 2574610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of obesity in patients receiving depot antipsychotics.
    Silverstone T; Smith G; Goodall E
    Br J Psychiatry; 1988 Aug; 153():214-7. PubMed ID: 2908236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of schizophrenia with depot preparations of fluphenazine, haloperidol, and risperidone among inpatients at state-operated psychiatric facilities.
    Citrome L; Jaffe A; Levine J
    Schizophr Res; 2010 Jun; 119(1-3):153-9. PubMed ID: 20347267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ten year outcomes of outpatients with schizophrenia on conventional depot antipsychotics: a systematic chart review.
    Uchida T; Suzuki T; Sakurai H; Tsutsumi C; Den R; Mimura M; Uchida H
    Int Clin Psychopharmacol; 2013 Sep; 28(5):261-6. PubMed ID: 23820334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implications of phenothiazine side effects: a study of antiparkinsonian agents in an older population.
    Martin IC
    Acta Psychiatr Scand; 1975 Feb; 51(2):110-8. PubMed ID: 235189
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Rapid and megadose neuroleptic therapy. Critical review].
    de Girolamo G
    Minerva Psichiatr; 1985; 26(4):323-6. PubMed ID: 2869395
    [No Abstract]   [Full Text] [Related]  

  • 11. ADP and arachidonic acid induced platelet aggregation in schizophrenia and atypical psychoses.
    Whalley LJ; Reading HW; Rosie R
    Psychol Med; 1984 Feb; 14(1):207-11. PubMed ID: 6143339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroendocrine tests during treatment with neuroleptic drugs. II. The TRH test.
    Braddock LE; Blake IM
    Br J Psychiatry; 1981 Nov; 139():404-7. PubMed ID: 6120732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Large variations of plasma levels during maintenance treatment with depot neuroleptics.
    Tuninger E; Levander S
    Br J Psychiatry; 1996 Nov; 169(5):618-21. PubMed ID: 8932892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of neuroleptic withdrawal on plasma prolactin: a possible marker of receptor adaptation.
    Kirkpatrick B; Buchanan RW; Maeda K; Carpenter WT; Jauch D; Tamminga CA
    Biol Psychiatry; 1989 Jun; 26(2):131-8. PubMed ID: 2567610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroleptic drug-induced changes in platelet levels.
    Holt RJ
    J Clin Psychopharmacol; 1984 Jun; 4(3):130-2. PubMed ID: 6145727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy with neuroleptics. Clinical and pharmacokinetic aspects with a particular view to depot preparations.
    Knudsen P
    Acta Psychiatr Scand Suppl; 1985; 322():51-75. PubMed ID: 2866666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of haloperidol and chlorpromazine on smooth muscle contractility, platelet aggregation and neuronal calcium current.
    Prokopenko RA; Mogilevich SE; Luik AI; Naydyenova IY; Batrak GN; Hawryluk BR; Degtiar VY
    Gen Physiol Biophys; 1995 Aug; 14(4):349-57. PubMed ID: 8720698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An open clinical trial with the long-acting neuroleptics flupenthixol decanoate and fluphenazine decanoate in the maintenance treatment of schizophrenia.
    Kong DS; Yeo SH
    Pharmatherapeutica; 1989; 5(6):371-9. PubMed ID: 2687894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lowest effective dose of depot neuroleptics.
    Hoencamp E; Haffmans PJ; Jansen GS
    Br J Psychiatry; 1992 Mar; 160():422-3. PubMed ID: 1348655
    [No Abstract]   [Full Text] [Related]  

  • 20. The ralationship between changes in 5-HT induced platelet aggregation and clinical state in patients treated with fluphenazine.
    Orr MW; Boullin DJ
    Br J Clin Pharmacol; 1976 Oct; 3(5):925-8. PubMed ID: 973988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.